Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca -- biotech's shares plunge
The FDA has slapped a clinical hold on a combo therapy using Advaxis’ $ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
